Our Science

World Leading Science

We’re fertility pioneers. Our research and technologies virtually doubled IVF success rates for patients in the mid-nineties and our constant search for innovations and breakthroughs continues to improve outcomes today. In fact, data compiled by the Australian and New Zealand Assisted Reproduction Database (ANZARD) shows that Genea's success rates give couples one of the best chances of taking home a healthy baby.* ANZARD conducts an annual review of IVF in Australia and New Zealand and we believe it is the only true independent basis for comparison.

Our expertise in the science of fertility is a direct result of our commitment to funding research. At Genea we have a long and proud history of investing in research and taking innovations from the lab into our clinics, enabling us to help more of our patients (and patients from clinics around the world) realise their dream of creating a family.

We invest by far the most of any Australian clinic with at least 10 per cent of our annual revenue on average going back into research - and substantially more over the past few years. That investment has led to many fertility breakthroughs over the years and that trend continues with some exciting new developments underway.

Routine Day 5 embryo transfers

Genea was the first clinic in Australia to introduce routine Day 5 embryo transfers. Growing the embryos in the lab a little longer before transferring them to the female lets us determine which embryos have the highest development potential and increases success rates. The time between Day 3 and Day 5 in an embryo’s life is critical because it’s when an embryo switches genetic control from the female’s genome to shared control between the female and male. This can be a point in the development of the embryo where problems occur and waiting to transfer embryos beyond it is far more successful. We have given our patients world leading success rates with this advancement for years, and other Australian clinics have only recently followed our lead.

Single embryo transfer

We were also the first clinic in Australia to introduce routine single embryo transfer. While many clinics transfer more than one embryo to try to improve their chances of success, our technology allows us to achieve higher success rates while transferring a single, carefully selected embryo.

 

All Genea's Fertility Specialists have undertaken specialist study and training to understand the different factors which might be impacting your fertility. They'll take the time to diagnose your condition, provide you with a range of options and work with you to devise the best treatment plan - just for you.

Genea Specialists

Vitrification versus the old slow freeze method

Genea was the first clinic in Australia (it’s becoming a little repetitive isn’t it?) to develop and routinely replace the old slow freezing method for embryos, eggs and sperm with the more efficient and successful vitrification process. The technology, which is similar to snap freezing, has dramatically increased survival rates for thawed embryos. We’ve been using it routinely since February 2006 but some clinics still use the outdated slow freeze method.

Fertility Technologies

We don't just have access to the latest technologies - we pioneer them. Here are just some of the technologies we’ve played a major role in developing over the years.

Incubators

Spending every day caring for your embryos, Genea’s embryologists are experts in what these precious potential babies need to survive and grow. So they developed a mini incubator that simulates the natural environment of human fallopian tubes by using low oxygen levels and introducing just the right amount of carbon dioxide to help embryos grow. The mini incubators or MINCs also maintain the optimal temperature to reduce stress on the embryo.

Genea Biomedx Culture Media - Gems®

The way we nurture and support eggs, sperm and embryos outside of the human body has been a key and consistent area of investment at Genea. For more than two decades, Genea scientists have been developing and refining culture media – the solutions which enable embryos to grow. Little surprise then that more than 600 clinics around the world nurture embryos using culture media developed by Genea. We’ve recently developed the next generation (Gems®) of this vital formula and have completed a rigorous clinical trial involving almost 1,200 Genea patients across all age groups and more than 15,000 eggs. The results are very positive, and Gems is now exclusively available at Genea clinics.

Genea Biomedx Automated Vitrification - Gavi®

In 2015, our sister company Genea Biomedx will begin producing and selling an automated vitrification instrument - the first in the world. Genea’s scientists started with a simple question: “What if vitrification didn’t have to be a complex, time consuming task?” And in answer to that question, they conceived and designed Gavi® - Genea Automated Vitrification Instrument - an instrument that automates the process of snap freezing embryos for use in later cycles. In the process, they’ve designed a tool which will standardise vitrification and, as a result, eliminate variation, and, we believe, ultimately improve outcomes for our patients.

Quite simply, if you want to ensure that you benefit from the very latest assisted conception research and technology you could do no better than come to Genea.

For further information on how we can help you, contact us today or fill in the form below.


  • Please send me information and notice of events relating to fertility.

Genea has legal obligations to protect your personal information and to provide you with details about how we deal with this information. Please read our Privacy Policy and Collection Statement.

 

* According to age-standardised analysis of the latest available data (2013) released September 2015 from the Australian and New Zealand Assisted Reproduction Database (ANZARD) and based on live births per embryo transfer for women using their own eggs.